<a href="https://laohu8.com/S/PALI">Palisade Bio Inc.</a> Introduces Phantom Equity Plan, Grants Phantom Units to Key Executives and Directors
Palisade Bio Inc. has introduced a new compensation plan involving the issuance of cash-settled phantom units to its employees, directors, and consultants. Approved by the Board of Directors on September 4, 2025, the Phantom Unit Plan allows for up to 10 million phantom units to be granted, each linked in value to the company's common stock. Under this plan, key executives, including CEO J.D. Finley, received 323,400 phantom units, while Chief Medical Officer Mitchell Jones and Senior Vice President of Finance Ryker Willie were awarded 289,000 and 137,600 units, respectively. The Board Chair and other independent directors also received allocations, solidifying the company's commitment to aligning its leadership's interests with long-term corporate performance.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Palisade Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-25-012687), on September 05, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。